Bristol-Myers Squibb PFD... (BMYMP)
PNK: BMYMP
· Real-Time Price · USD
831.56
26.56 (3.30%)
At close: Apr 25, 2025, 1:34 PM
Company Description
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders.
A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development.
Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group.
Bristol-Myers Squibb PFD CONV 2
| Country | United States |
| IPO Date | Dec 8, 2003 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | n/a |
| CEO | n/a |
Contact Details
Address: No Address available No city data available, Delaware United States | |
| Website | n/a |
Stock Details
| Ticker Symbol | BMYMP |
| Exchange | PNK |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0000014272 |
| CUSIP Number | n/a |
| ISIN Number | US1101222073 |
| Employer ID | 22-0790350 |
| SIC Code | 2834 |
Key Executives
No executives data available.Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 29, 2025 | 4 | Filing |
| Apr 25, 2025 | SCHEDULE 13G | Filing |
| Apr 24, 2025 | 10-Q | Quarterly Report |
| Apr 24, 2025 | 8-K | Current Report |
| Apr 23, 2025 | SC TO-T/A | [Amend] Filing |
| Apr 17, 2025 | SC TO-T/A | [Amend] Filing |
| Apr 17, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Apr 15, 2025 | DEFA14A | Filing |
| Apr 14, 2025 | SC TO-T | Filing |
| Apr 03, 2025 | 4 | Filing |